Eli Lilly & Co.’s stock rose 1.6% Wednesday, after the drug company announced plans to expand its U.S. manufacturing sites by adding four more locations this year, along with 13,000 high-wage jobs.

Eli Lilly has enrolled the first patient into a phase 3 trial that is seeking to repurpose arthritis drug Olumiant as a treatment for people with COVID-19. The 400-patient trial will test Olumiant ...

Leveraging the power of the best AI website builders can help you build a better website faster than ever before. Wix tops the list thanks to its offering of powerful AI tools and a fully text ...

The AI industry is doing its best to will "agents"—pieces of AI-driven software that can perform multistep actions on your behalf—into reality. Several tech companies, including Google ...

Eli Lilly stock has advanced more than 200% over the past three years thanks to the company’s dominance in the weight loss drug market. Lilly may face more competitors down the road in this high ...

Twenty-five years ago this week, the Nasdaq Composite Index hit its dot-com-era peak after soaring more than 500% in five years. Its subsequent collapse was swift and brutal. Small investors lured ...

Companies are increasingly asking their potential technology hires: Do you know how to work with AI? Nearly 1 in 4 U.S. tech jobs posted so far this year are seeking employees with artificial ...

March 10 (Reuters) - Eli Lilly (LLY.N), opens new tab plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and Mexico in the second half of ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of ...